Pharmacokinetics and protein binding of MPT0B292

Yu En Tien, Chan Jung Li, Jing Ping Liou, Jang Yang Chang, Jin Ding Huang

Research output: Contribution to journalArticle

Abstract

MPT0B292 was identified through screening of compounds able selectively to acetylate α-tubulins in cells and it exhibited potent anti-tumor, anti-angiogenesis and anti-metastatic effects in vitro and in vivo. Because of its poor water solubility, MPT0B292 is difficult to formulate with conventional approaches and hence difficulties are experienced in research practices. MPT0B292 was mixed with albumin in an aqueous solvent to form drug albumin nanoparticles with a size range around 333 nm. Unbound fractions of these nanoparticles were investigated in different or the same albumin concentration solutions. Unlike most drugs, the binding of MPT0B292 in human serum albumin increased with increasing drug concentrations. An analytical method was also developed and validated to determine MPT0B292 in rat plasma. This analytical method was applied successfully to the intravenous pharmacokinetic study of MPT0B292 in rats. A single dose study was regularly done to characterize the pharmacokinetic properties of the drug. Additionally, a novel i.v. infusion study was carried out to verify the extraction ratio of MPT0B292. The pharmacokinetic analysis revealed that MPT0B292 was a high extraction ratio drug with high systemic clearance, a high volume of distribution and a short half-life in rats.

Original languageEnglish
JournalBiopharmaceutics and Drug Disposition
DOIs
Publication statusAccepted/In press - 2017

Fingerprint

Protein Binding
Pharmacokinetics
Albumins
Pharmaceutical Preparations
Nanoparticles
Tubulin
Serum Albumin
Solubility
Half-Life
Water
Research
Neoplasms

Keywords

  • Disposition
  • Human serum albumin
  • MPT0B292
  • Pharmacokinetic
  • Protein binding

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

Pharmacokinetics and protein binding of MPT0B292. / Tien, Yu En; Li, Chan Jung; Liou, Jing Ping; Chang, Jang Yang; Huang, Jin Ding.

In: Biopharmaceutics and Drug Disposition, 2017.

Research output: Contribution to journalArticle

Tien, Yu En ; Li, Chan Jung ; Liou, Jing Ping ; Chang, Jang Yang ; Huang, Jin Ding. / Pharmacokinetics and protein binding of MPT0B292. In: Biopharmaceutics and Drug Disposition. 2017.
@article{bbda020bee2f4f3eb20f2fba02d3d0b9,
title = "Pharmacokinetics and protein binding of MPT0B292",
abstract = "MPT0B292 was identified through screening of compounds able selectively to acetylate α-tubulins in cells and it exhibited potent anti-tumor, anti-angiogenesis and anti-metastatic effects in vitro and in vivo. Because of its poor water solubility, MPT0B292 is difficult to formulate with conventional approaches and hence difficulties are experienced in research practices. MPT0B292 was mixed with albumin in an aqueous solvent to form drug albumin nanoparticles with a size range around 333 nm. Unbound fractions of these nanoparticles were investigated in different or the same albumin concentration solutions. Unlike most drugs, the binding of MPT0B292 in human serum albumin increased with increasing drug concentrations. An analytical method was also developed and validated to determine MPT0B292 in rat plasma. This analytical method was applied successfully to the intravenous pharmacokinetic study of MPT0B292 in rats. A single dose study was regularly done to characterize the pharmacokinetic properties of the drug. Additionally, a novel i.v. infusion study was carried out to verify the extraction ratio of MPT0B292. The pharmacokinetic analysis revealed that MPT0B292 was a high extraction ratio drug with high systemic clearance, a high volume of distribution and a short half-life in rats.",
keywords = "Disposition, Human serum albumin, MPT0B292, Pharmacokinetic, Protein binding",
author = "Tien, {Yu En} and Li, {Chan Jung} and Liou, {Jing Ping} and Chang, {Jang Yang} and Huang, {Jin Ding}",
year = "2017",
doi = "10.1002/bdd.2067",
language = "English",
journal = "Biopharmaceutics and Drug Disposition",
issn = "0142-2782",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Pharmacokinetics and protein binding of MPT0B292

AU - Tien, Yu En

AU - Li, Chan Jung

AU - Liou, Jing Ping

AU - Chang, Jang Yang

AU - Huang, Jin Ding

PY - 2017

Y1 - 2017

N2 - MPT0B292 was identified through screening of compounds able selectively to acetylate α-tubulins in cells and it exhibited potent anti-tumor, anti-angiogenesis and anti-metastatic effects in vitro and in vivo. Because of its poor water solubility, MPT0B292 is difficult to formulate with conventional approaches and hence difficulties are experienced in research practices. MPT0B292 was mixed with albumin in an aqueous solvent to form drug albumin nanoparticles with a size range around 333 nm. Unbound fractions of these nanoparticles were investigated in different or the same albumin concentration solutions. Unlike most drugs, the binding of MPT0B292 in human serum albumin increased with increasing drug concentrations. An analytical method was also developed and validated to determine MPT0B292 in rat plasma. This analytical method was applied successfully to the intravenous pharmacokinetic study of MPT0B292 in rats. A single dose study was regularly done to characterize the pharmacokinetic properties of the drug. Additionally, a novel i.v. infusion study was carried out to verify the extraction ratio of MPT0B292. The pharmacokinetic analysis revealed that MPT0B292 was a high extraction ratio drug with high systemic clearance, a high volume of distribution and a short half-life in rats.

AB - MPT0B292 was identified through screening of compounds able selectively to acetylate α-tubulins in cells and it exhibited potent anti-tumor, anti-angiogenesis and anti-metastatic effects in vitro and in vivo. Because of its poor water solubility, MPT0B292 is difficult to formulate with conventional approaches and hence difficulties are experienced in research practices. MPT0B292 was mixed with albumin in an aqueous solvent to form drug albumin nanoparticles with a size range around 333 nm. Unbound fractions of these nanoparticles were investigated in different or the same albumin concentration solutions. Unlike most drugs, the binding of MPT0B292 in human serum albumin increased with increasing drug concentrations. An analytical method was also developed and validated to determine MPT0B292 in rat plasma. This analytical method was applied successfully to the intravenous pharmacokinetic study of MPT0B292 in rats. A single dose study was regularly done to characterize the pharmacokinetic properties of the drug. Additionally, a novel i.v. infusion study was carried out to verify the extraction ratio of MPT0B292. The pharmacokinetic analysis revealed that MPT0B292 was a high extraction ratio drug with high systemic clearance, a high volume of distribution and a short half-life in rats.

KW - Disposition

KW - Human serum albumin

KW - MPT0B292

KW - Pharmacokinetic

KW - Protein binding

UR - http://www.scopus.com/inward/record.url?scp=85013768233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013768233&partnerID=8YFLogxK

U2 - 10.1002/bdd.2067

DO - 10.1002/bdd.2067

M3 - Article

C2 - 28144964

AN - SCOPUS:85013768233

JO - Biopharmaceutics and Drug Disposition

JF - Biopharmaceutics and Drug Disposition

SN - 0142-2782

ER -